

FACSIMILE COVER SHEET

RECEIVED
CENTRAL FAX CENTER

JAN 12 2006

NORRIS MCLAUGHLIN & MARCUS, P.A.

875 Third Avenue

18th Floor

New York, NY 10022

Tel.: (212) 808-0700

Fax.: (212) 808-0844

Date: January 12, 2006

To: Examiner Susan NMN Ungar
US Patent and Trademark Office
Fax: 571-273-8300

Subject: USSN: 10/069,896
Our Ref.: 103219-6

From: Paul Lim

Comments: Filing of: response to restriction requirement (2 pgs.)

If you have any questions or need further information, please contact us.

You should receive 3 pages including this cover sheet.

The information contained in this facsimile message is intended only for the personal and confidential use of the recipient(s) named above. This message may be an attorney-client communication and as such is privileged and confidential. If the reader of this message is not the intended recipient or an agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately at the number above and discard the original message.

CERTIFICATE OF MAILING OR TRANSMISSION BY FACSIMILE	
I hereby certify that this correspondence is being facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below to Fax Number 571-273-8300	
<u>Agata Gliniska</u> Agata Gliniska	Date <u>JAN. 12, 2006</u>

Attorney Docket No.: 103219-2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NO. : 10/069,896
APPLICANT : Walter Birchmeier
FILED : April 17, 2002
EXAMINER : Susan N. Ungar
ART UNIT : 1642
FOR : AGENTS FOR TREATING HUMAN DISEASES,
ESPECIALLY FOR TREATING TUMORS SUCH AS
COLONIC CANCERS AND MELANOMAS OR FOR
REGENERATING TISSUE AND PROMOTING HAIR
GROWTH

RECEIVED
CENTRAL FAX CENTER

JAN 12 2006

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

January 12, 2006

RESPONSE TO RESTRICTION REQUIREMENT

SIR:

In response to the communication dated August 11, 2005, Applicants hereby provisionally elect to prosecute cefamandole. However, as stated earlier, the restriction requirement is traversed to the extent that the 4 compounds of the group of substances 1A ("molecule-class 1A") from the positive list are considered separate species. The group of cefamandoles is active in the inhibition of the beta-catenin binding. The class as such shares a chemical common motif (i.e. the cefamandole-scaffold).